Clinical Utility of Circulating Tumor DNA in Advanced Rare Cancers

PurposePatients with advanced/relapsed rare cancers have few treatment options. Analysis of circulating tumor DNA in plasma may identify actionable genomic biomarkers using a non-invasive approach.Patients and MethodsRare cancer patients underwent prospective plasma-based NGS testing. Tissue NGS to...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Hitomi Sumiyoshi Okuma, Kan Yonemori, Yuki Kojima, Maki Tanioka, Kazuki Sudo, Emi Noguchi, Susumu Hijioka, Keiko Wakakuwa, Ken Kato, Akihiro Hirakawa, Aya Kuchiba, Takashi Kubo, Hitoshi Ichikawa, Akihiko Yoshida, Yasushi Yatabe, Kenichi Nakamura, Hiroyuki Mano, Noboru Yamamoto, Yasuhiro Fujiwara
Format:	article
Langue:	EN
Publié:	Frontiers Media S.A. 2021
Sujets:	rare cancer CtDNA (circulating tumor DNA) precision medicine soft tissue sarcoma targeted therapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Accès en ligne:	https://doaj.org/article/35ecf0472ced44858aa96591a8e7fa2a
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!

Clinical Utility of Circulating Tumor DNA in Advanced Rare Cancers

Documents similaires